OGEN Oragenics Inc.
Listings ·
NYSE American notified Oragenics on August 26, 2026 that it is not in compliance with two continued listing standards on stockholders' equity. The company has 45 days to submit a compliance plan and says it intends to do so.
Oragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026. The company's June 29, 2026 annual meeting included a vote on authority for a reverse stock split of one-for-two to one-for-fifty.
Oragenics signed a non-binding letter of intent to license certain indications of CardioDialysis from Sigyn Therapeutics for traumatic brain injury. The proposed terms include 3,250,000 restricted preferred shares and a 3% royalty for six years.
The first patient in the Phase IIa trial of ONP-002 was dosed at Mackay Hospital in Australia, the first site activated, with two more Australian sites expected to activate in the second quarter.
NYSE American told Oragenics on October 20, 2025 that it again meets stockholders' equity standards. The company also paid Ladenburg Thalmann $700,000 to settle a dispute over a $2,500,000 fee claim.
Net proceeds were about $15.2 million after fees and expenses. The company plans to start a Phase IIa concussion trial in Q3 2025.
Oragenics closed a registered offering of 660,000 Series H preferred shares and warrants on July 2, 2025, for about $16.5 million gross. The preferred converts at $2.50 a share, the conversion price has no floor, and Dawson James Securities took 7.00% of gross proceeds as placement agent.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.4 million | $4.1 million |
| Net income (loss) | -$9.8 million | -$10.6 million |
| Cash from operations | -$9.2 million | -$8.6 million |
| Cash and equivalents | $4.4 million | $864,840 |
| Short-term investments | $4.0 million |
Our latest story on this, dated Jul 6, 2026: "Oragenics names John Spencer CFO and reports annual meeting votes". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 2, 2025: "Oragenics closes public offering of Series H preferred with about $16.5 million gross proceeds". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 28, 2026: "Oragenics receives NYSE American deficiency letter on equity". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 21, 2025: "Oragenics regains NYSE American equity compliance, settles Ladenburg fee claim for $700,000". The story links the filing or release it is based on. Read the story.
Oragenics Inc. trades under the ticker OGEN on AMEX.
Oragenics Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for Oragenics Inc. is 1174940. Its filings are on SEC EDGAR.
4,511,957 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Oragenics Inc. under United States.
Our directory classifies Oragenics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Oragenics Inc. is US6840236094.
aibio.space lists Oragenics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as FL.
Oragenics Inc. reported a net loss of $9.8 million for the fiscal year ended Dec 31, 2025, and used $9.2 million of cash in operations, per its annual report to the SEC.
$2.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 1.01,5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 1.01,5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio